The global seasonal influenza market is forecast to be worth $4.3bn by 2025. This figure is unsurprising considering the enormous economic costs of flu each year.
On average, the total estimated annual economic burden of influenza to the US healthcare system and society is $11.2 billion, comprising $3.2 billion in direct medical costs and $8 billion in indirect costs. The CDC (Centre for Disease Control and Prevention) recommends that every person from the age of six months onwards has a flu vaccine, but actual vaccination coverage hovers around 50%
In the UK, six million working days are lost to seasonal influenza in an average winter, yet uptake amongst the under-65s has been steadily declining in recent years. Many cite difficulties with getting an appointment at their GP’s surgery, where the vast majority of flu jabs are still administered.